In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™).
OBJECTIVE
INTERCEPT Blood System™ is a pathogen inactivation system for blood components. The initial approval required a platelet component to be suspended in a combination of plasma and Platelet additive Solution/PAS-III. Improved platelet storage has been reported with Mg++ and K+ supplementation (PAS-IIIM). This study validated the use of INTERCEPT™/PAS-IIIM for apheresis and pooled buffy-coat platelet components.


METHODS
The platelet dose and pH throughout 5 days of storage met the European and French requirements for quality standards.


CONCLUSIONS
Additional metabolic and activation assessments of the treated platelets confirmed the previously reported superiority of PAS-IIIM over PAS-III, but extended it to the INTERCEPT™ process.
Chavarin
P
P
EFS Auvergne Loire, Saint- Etienne, France.
Cognasse
F
F
Argaud
C
C
Vidal
M
M
De Putter
C
C
Boussoulade
F
F
Ripaud
C
C
Acquart
S
S
Lin
L
L
Garraud
O
O
D001781:Blood Component Removal; D001792:Blood Platelets; D001793:Blood Preservation; D004203:Disinfection / Q000295:instrumentation / Q000379:methods; D005260:Female; D011564:Furocoumarins / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D013997:Time Factors; D014466:Ultraviolet Rays
D011564:Furocoumarins; C118577:amotosalen